Opinions of Primary Care Clinicians and Psychiatrists on Monitoring the Metabolic Effects of Antipsychotics

References

1. 1.↵
   1. Colton CW,
   2. Manderscheid RW

   . Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3:A42.

   OpenUrlPubMed
2. 2.↵
   1. Brown S,
   2. Kim M,
   3. Mitchell C,
   4. Inskip H

   . Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010;196:116–121.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Walker ER,
   2. McGee RE,
   3. Druss BG

   . Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72:334–341.

   OpenUrl
4. 4.↵
   1. Olfson M,
   2. Gerhard T,
   3. Huang C,
   4. Crystal S,
   5. Stroup TS

   . Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72:1172–1181.

   OpenUrl
5. 5.↵
   1. Lawrence D,
   2. Hancock KJ,
   3. Kisely S

   . The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ. 2013;346:f2539.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Laursen TM,
   2. Nordentoft M,
   3. Mortensen PB

   . Excess early mortality in schizophrenia. Ann Rev Clin Psychol 2014;10:425–48.

   OpenUrl
7. 7.↵
   1. McEvoy JP,
   2. Meyer JM,
   3. Goff DC,
   4. et al

   . Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19–32.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Newcomer JW,
   2. Hennekens CH

   . Severe mental illness and risk of cardiovascular disease. JAMA. 2007;298:1794–1796.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Mitchell AJ,
   2. Vancampfort D,
   3. Sweers K,
   4. van Winkel R,
   5. Yu W,
   6. De Hert M

   . Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders–a systematic review and meta-analysis. Schizophr Bull. 2013;39:306–318.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Correll CU,
    2. Joffe BI,
    3. Rosen LM,
    4. Sullivan TB,
    5. Joffe RT

    . Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry. 2015;14:56–63.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Vancampfort D,
    2. Stubbs B,
    3. Mitchell AJ,
    4. et al

    . Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339–347.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Green AI,
    2. Lieberman JA,
    3. Hamer RM,
    4. et al

    . Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006;86:234–243.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Kahn RS,
    2. Fleischhacker WW,
    3. Boter H,
    4. et al

    . Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–1097.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Perez-Iglesias R,
    2. Mata I,
    3. Pelayo-Teran JM,
    4. et al

    . Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naive population. Schizophr Res. 2009;107:115–121.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Oriot P,
    2. Feys JL,
    3. Mertens de Wilmars S,
    4. et al

    . Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diabetes Metab. 2008;34:490–496.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Nasrallah HA,
    2. Meyer JM,
    3. Goff DC,
    4. et al

    . Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86:15–22.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Smith DJ,
    2. Langan J,
    3. McLean G,
    4. Guthrie B,
    5. Mercer SW

    . Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open. 2013;3:e002808.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Briskman I,
    2. Bar G,
    3. Boaz M,
    4. Shargorodsky M

    . Impact of co-morbid mental illness on the diagnosis and management of patients hospitalized for medical conditions in a general hospital. Int J Psychiatry Med 2012;43:339–48.

    OpenUrlPubMed
19. 19.↵
    1. Citrome L,
    2. Volavka J

    . Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. J Clin Psychiatry. 2005;66:1073–1074.

    OpenUrlPubMedWeb of Science
20. 20.↵
    1. Parks J,
    2. Radke A.Q.,
    3. Mazade N.A.

    Measurement of health status for people with serious mental illness. Alexandria, VA: National Association of State Mental Health Program Directors; 2008.
21. 21.↵
    1. Green CA,
    2. Yarborough BJ,
    3. Leo MC,
    4. et al

    . The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry. 2015;172:71–81.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Daumit GL,
    2. Dickerson FB,
    3. Wang NY,
    4. et al

    . A behavioral weight-loss intervention in persons with serious mental illness. N Engl J MEd. 2013;368:1594–1602.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Buckley PF,
    2. Miller DD,
    3. Singer B,
    4. Arena J,
    5. Stirewalt EM

    . Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res. 2005;79:281–288.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Essock SM,
    2. Covell NH,
    3. Leckman-Westin E,
    4. et al

    . Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York state. Psychiatr Serv. 2009;60:1595–1602.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Morrato EH,
    2. Druss B,
    3. Hartung DM,
    4. et al

    . Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry. 2010;67:17–24.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Mangurian C,
    2. Newcomer JW,
    3. Vittinghoff E,
    4. et al

    . Diabetes screening among underserved adults with severe mental illness who take antipsychotic medications. JAMA Intern Med. 2015;175:1977–1979.

    OpenUrl
27. 27.↵
    1. Mangurian C,
    2. Giwa F,
    3. Shumway M,
    4. et al

    . Primary care providers' views on metabolic monitoring of outpatients taking antipsychotic medication. Psychiatr Serv. 2013;64:597–599.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Parameswaran SG,
    2. Chang C,
    3. Swenson AK,
    4. Shumway M,
    5. Olfson M,
    6. Mangurian CV

    . Roles in and barriers to metabolic screening for people taking antipsychotic medications: a survey of psychiatrists. Schizophr Res. 2013;143:395–396.

    OpenUrl
29. 29.↵
    1. Arbuckle MR,
    2. Gameroff MJ,
    3. Marcus SC,
    4. West JC,
    5. Wilk J,
    6. Olfson M

    . Psychiatric opinion and antipsychotic selection in the management of schizophrenia. Psychiatr Services. 2008;59:561–565.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Olfson M,
    2. Marcus SC,
    3. Wilk J,
    4. West JC

    . Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. Psychiatr Serv. 2006;57:205–211.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. McGinty EE,
    2. Baller J,
    3. Azrin ST,
    4. Juliano-Bult D,
    5. Daumit GL

    . Quality of medical care for persons with serious mental illness: a comprehensive review. Schizophr Res. 2015;165:227–235.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Amiel JM,
    2. Pincus HA

    . The medical home model: new opportunities for psychiatric services in the United States. Curr Opin Psychiatry. 2011;24:562–568.

    OpenUrlPubMed
33. 33.↵
    1. Handelsman Y,
    2. Bloomgarden ZT,
    3. Grunberger G,
    4. et al

    . American Association of Clinical Endocrinologists and American College of Endocrinology–clinical practice guidelines for developing a diabetes mellitus comprehensive care plan–2015. Endocrine Practice. 2015;21.s1:1–87.

    OpenUrl